右美托咪定用于慢性阻塞性肺疾病急性加重期肺肾两虚型患者无创辅助通气镇静的临床观察

Clinical observation on dexmedetomidine for chronic obstructive pulmonary disease with acute exacerbation of lung and kidney deficiency type two patients with of noninvasive ventilation sedation

[目的]观察右美托咪定用于无创辅助通气的慢性阻塞性肺疾病急性加重期(AECOPD)肺肾两虚型患者镇静作用的临床有效性及安全性。[方法]选取近两年内本院重症监护病房(ICU)收治的64例需无创辅助通气的AECOPD肺肾两虚型住院患者,将其随机分成观察组和对照组,每组均为32例,所有病例均按AECOPD最新指南在采取支气管扩张剂、全身糖皮质激素和抗生素等药物的常规治疗的基础上,给予患者无创通气支持,同时予观察组患者右美托咪定镇静治疗。[结果]右美托咪定观察组的临床治疗效果总体上优于对照组,且患者依从性更好,舒适度更高,缩短带呼吸机时间,缩短ICU住院时间。[结论]右美托咪定具有较好的临床疗效和安全性,镇静效果满意,可作为AECOPD肺肾两虚型患者无创辅助通气镇静时优先选择的药物之一。

[Objective] To observe the effects of dexmedetomidine for noninvasive ventilation in chronic obstructive pulmonary disease with acute exacerbation(AECOPD) clinical efficacy and safety of lung and kidney deficiency type two patients with sedative. [Methods]To select in the past two years in our hospital intensive care unit(ICU) from 64 cases of noninvasive ventilation in AECOPD patients, they were randomly divided into observation group and control group, each group has 32 cases, all cases were in AECOPD latest guide in based on the routine treatment taking bronchiectasis agent, systemic corticosteroids and antibiotics and other drugs. All the patients were treated with noninvasive ventilatory support, also given to the observation group patients with dexmedetomidine sedation. [Results]Dexmedetomidine set in the observation group, the clinical therapeutic effect of overall was better than the control group and better patient compliance, more comfort and reduce the chances of a cannula, shortens the time machine, shorten the ICU hospitalization time.[Conclusion] Dexmedetomidine set has good clinical efficacy and safety, sedative effect, as in patients with AECOPD noninvasive assisted ventilation calm when the first choice of the drugs.